Five-year follow-up of a phase II study of DA-EPOCH-R with high-dose MTX in CD5-positive DLBCL

Kana Miyazaki; Rika Sakai; Noriko Iwaki; Go Yamamoto; Kayoko Murayama; Momoko Nishikori; Kazutaka Sunami; Isao Yoshida; Hiroki Yano; Naoki Takahashi; Akinao Okamoto; Saori Munemoto; Aiko Sawazaki; Youko Suehiro; Noriko Fukuhara; Atsushi Wake; Ayako Arai; Yasufumi Masaki; Kohtaro Toyama; Akihiro Yokoyama; Hiroko Tsunemine; Yuichi Hasegawa; Kenji Matsumoto; Tomomi Yamada; Yuki Nishimura; Satoshi Tamaru; Naoko Asano; Kohta Miyawaki; Koji Izutsu; Tomohiro Kinoshita; Ritsuro Suzuki; Koichi Ohshima; Koji Kato; Naoyuki Katayama; Motoko Yamaguchi

doi:10.1111/cas.15784

Five-year follow-up of a phase II study of DA-EPOCH-R with high-dose MTX in CD5-positive DLBCL

Kana Miyazaki
, Rika Sakai
, Noriko Iwaki
, Go Yamamoto
, Kayoko Murayama
, Momoko Nishikori
, Kazutaka Sunami
, Isao Yoshida
, Hiroki Yano
, Naoki Takahashi
, Akinao Okamoto
, Saori Munemoto
, Aiko Sawazaki
, Youko Suehiro
, Noriko Fukuhara
, Atsushi Wake
, Ayako Arai
, Yasufumi Masaki
, Kohtaro Toyama
, Akihiro Yokoyama

Hiroko Tsunemine, Yuichi Hasegawa, Kenji Matsumoto, Tomomi Yamada, Yuki Nishimura, Satoshi Tamaru, Naoko Asano, Kohta Miyawaki, Koji Izutsu, Tomohiro Kinoshita, Ritsuro Suzuki, Koichi Ohshima, Koji Kato, Naoyuki Katayama, Motoko Yamaguchi

Research output: Contribution to journal › Letter › peer-review

4 Citations (Scopus)

Original language	English
Pages (from-to)	2689-2691
Number of pages	3
Journal	Cancer science
Volume	114
Issue number	6
DOIs	https://doi.org/10.1111/cas.15784
Publication status	Published - 06-2023
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

All Science Journal Classification (ASJC) codes

Oncology
Cancer Research

Access to Document

10.1111/cas.15784

Cite this

Miyazaki, K., Sakai, R., Iwaki, N., Yamamoto, G., Murayama, K., Nishikori, M., Sunami, K., Yoshida, I., Yano, H., Takahashi, N., Okamoto, A., Munemoto, S., Sawazaki, A., Suehiro, Y., Fukuhara, N., Wake, A., Arai, A., Masaki, Y., Toyama, K., ... Yamaguchi, M. (2023). Five-year follow-up of a phase II study of DA-EPOCH-R with high-dose MTX in CD5-positive DLBCL. Cancer science, 114(6), 2689-2691. https://doi.org/10.1111/cas.15784

@article{7f75e161d990483b9d5f89937bf93c60,

title = "Five-year follow-up of a phase II study of DA-EPOCH-R with high-dose MTX in CD5-positive DLBCL",

author = "Kana Miyazaki and Rika Sakai and Noriko Iwaki and Go Yamamoto and Kayoko Murayama and Momoko Nishikori and Kazutaka Sunami and Isao Yoshida and Hiroki Yano and Naoki Takahashi and Akinao Okamoto and Saori Munemoto and Aiko Sawazaki and Youko Suehiro and Noriko Fukuhara and Atsushi Wake and Ayako Arai and Yasufumi Masaki and Kohtaro Toyama and Akihiro Yokoyama and Hiroko Tsunemine and Yuichi Hasegawa and Kenji Matsumoto and Tomomi Yamada and Yuki Nishimura and Satoshi Tamaru and Naoko Asano and Kohta Miyawaki and Koji Izutsu and Tomohiro Kinoshita and Ritsuro Suzuki and Koichi Ohshima and Koji Kato and Naoyuki Katayama and Motoko Yamaguchi",

note = "Funding Information: This study was supported by grants‐in‐aid from the Japan Agency for Medical Research and Development, AMED (JP15Ack0106157, JP16ck0106157, JP17ck0106157, JP18ck0106439), the Ministry of Labour, Health, and Welfare of Japan (201438142A), the director of Mie University Hospital (2012, 2013), and the National Cancer Center Research and Development Fund (26‐A‐4, 29‐A‐3). Funding Information: We wish to thank Takuya Matsunaga (Hokuou Hospital), Noriko Usui (The Jikei University School of Medicine), and Akiko Kada (Nagoya Medical Center) as members of the Data and Safety Monitoring Board.",

year = "2023",

month = jun,

doi = "10.1111/cas.15784",

language = "English",

volume = "114",

pages = "2689--2691",

journal = "Cancer science",

issn = "1347-9032",

publisher = "Wiley-Blackwell",

number = "6",

}

Miyazaki, K, Sakai, R, Iwaki, N, Yamamoto, G, Murayama, K, Nishikori, M, Sunami, K, Yoshida, I, Yano, H, Takahashi, N, Okamoto, A, Munemoto, S, Sawazaki, A, Suehiro, Y, Fukuhara, N, Wake, A, Arai, A, Masaki, Y, Toyama, K, Yokoyama, A, Tsunemine, H, Hasegawa, Y, Matsumoto, K, Yamada, T, Nishimura, Y, Tamaru, S, Asano, N, Miyawaki, K, Izutsu, K, Kinoshita, T, Suzuki, R, Ohshima, K, Kato, K, Katayama, N & Yamaguchi, M 2023, 'Five-year follow-up of a phase II study of DA-EPOCH-R with high-dose MTX in CD5-positive DLBCL', Cancer science, vol. 114, no. 6, pp. 2689-2691. https://doi.org/10.1111/cas.15784

TY - JOUR

T1 - Five-year follow-up of a phase II study of DA-EPOCH-R with high-dose MTX in CD5-positive DLBCL

AU - Miyazaki, Kana

AU - Sakai, Rika

AU - Iwaki, Noriko

AU - Yamamoto, Go

AU - Murayama, Kayoko

AU - Nishikori, Momoko

AU - Sunami, Kazutaka

AU - Yoshida, Isao

AU - Yano, Hiroki

AU - Takahashi, Naoki

AU - Okamoto, Akinao

AU - Munemoto, Saori

AU - Sawazaki, Aiko

AU - Suehiro, Youko

AU - Fukuhara, Noriko

AU - Wake, Atsushi

AU - Arai, Ayako

AU - Masaki, Yasufumi

AU - Toyama, Kohtaro

AU - Yokoyama, Akihiro

AU - Tsunemine, Hiroko

AU - Hasegawa, Yuichi

AU - Matsumoto, Kenji

AU - Yamada, Tomomi

AU - Nishimura, Yuki

AU - Tamaru, Satoshi

AU - Asano, Naoko

AU - Miyawaki, Kohta

AU - Izutsu, Koji

AU - Kinoshita, Tomohiro

AU - Suzuki, Ritsuro

AU - Ohshima, Koichi

AU - Kato, Koji

AU - Katayama, Naoyuki

AU - Yamaguchi, Motoko

N1 - Funding Information: This study was supported by grants‐in‐aid from the Japan Agency for Medical Research and Development, AMED (JP15Ack0106157, JP16ck0106157, JP17ck0106157, JP18ck0106439), the Ministry of Labour, Health, and Welfare of Japan (201438142A), the director of Mie University Hospital (2012, 2013), and the National Cancer Center Research and Development Fund (26‐A‐4, 29‐A‐3). Funding Information: We wish to thank Takuya Matsunaga (Hokuou Hospital), Noriko Usui (The Jikei University School of Medicine), and Akiko Kada (Nagoya Medical Center) as members of the Data and Safety Monitoring Board.

PY - 2023/6

Y1 - 2023/6

UR - https://www.scopus.com/pages/publications/85150804785

UR - https://www.scopus.com/pages/publications/85150804785#tab=citedBy

U2 - 10.1111/cas.15784

DO - 10.1111/cas.15784

M3 - Letter

C2 - 36929591

AN - SCOPUS:85150804785

SN - 1347-9032

VL - 114

SP - 2689

EP - 2691

JO - Cancer science

JF - Cancer science

IS - 6

ER -

Five-year follow-up of a phase II study of DA-EPOCH-R with high-dose MTX in CD5-positive DLBCL

UN SDGs

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Cite this